ORIG3N, an innovative biotech company that creating the world’s largest blood cell repository for induced pluripotent stem cell (iPS cell) production. I first met James Lovgren, Chief Business Officer of ORIG3N, at the World Stem Cell Summit in 2015. As a result of that connection and conversation, I am pleased to share this interview with him below. [Read more…]
Ncardia and Evotec Enter Licencing Agreement for Disease Modelling Using iPS Cells
December 04, 2017, GOSSELIES, Belgium—Ncardia, a leader in standardised, validated iPSC assays for safety, phenotypic screening and disease modeling, announced today that they entered into a global non-exclusive IP licensing agreement with Evotec (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809). The financial terms of the agreements are not disclosed. [Read more…]
Fate Therapeutics Progress iPSC-Derived Cancer Immunotherapy Pipeline
Founded in 2007 by Rudolf Jaenisch with backing from Arch Venture Partners, Fate Therapeutics’ corporate headquarters are in San Diego, California. It also has a subsidiary in Ottawa, Canada. Fate Therapeutics is an innovative biotechnology company developing novel stem cell modulators and biologic or small molecule compounds that guide cell fate. [Read more…]
Top 10 Differentiators for Axiogenesis within the Global iPSC Marketplace
Groundbreaking experimentation in 2006 by Shinya Yamanaka (Kyoto University, Japan) led to the introduction of induced pluripotent stem cells (iPSCs). These are adult cells that are isolated and then reprogrammed into embryonic-like stem cells through the expression of a specific set of embryonic genes. Yamanaka’s discovery, which earned him the Nobel prize in 2012, enabled the use of human cells in stem cell science, bypassing the use of embryonic stem cells (ESCs). Without the ethical problems associated with ESCs, a large and diverse market for human iPSC research tools has emerged.
Founded in 2001 and headquartered in Cologne, Germany, Axiogenesis initially focused on generating mouse embryonic stem cell derived cells and assays. After Yamanaka’s groundbreaking iPSC technology became available, Axiogenesis was the first European company to license and adopt Yamanaka’s iPSC technology in 2010. [Read more…]
Cynata Therapeutics Secures $6M in Capital Raise, $10M with Payment from FUJIFILM
Cynata Successfully Completes Capital Raising
Melbourne, Australia; 23 January 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), has successfully completed a placement of approximately 9.23 million fully-paid ordinary shares at a price of $0.65, for gross proceeds of A$6.0 million before costs (“Placement”). The Placement was made to existing and new sophisticated and institutional investors. Settlement of the Placement, which was heavily over-subscribed, is expected to occur on or about 27 January 2017 with the shares to be issued on 30 January 2017. The Placement shares will be issued under Cynata’s existing placement capacity under Listing Rules 7.1 and 7.1A, and accordingly will not require shareholder approval. [Read more…]
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 19
- Next Page »